Assessing the Time-Course of Dexmedetomidine-Induced Analgesia Via EEG
Status:
NOT_YET_RECRUITING
Trial end date:
2025-05-26
Target enrollment:
Participant gender:
Summary
Objective: To investigate the temporal dynamics of dexmedetomidine's analgesic effects in the brain using EEG.
Methods: Eligible patients scheduled for total hip arthroplasty under intrathecal anesthesia received a continuous infusion of DEX at 1.5 g/(kgh) for 15 minutes before neuraxial puncture, followed by an additional 15-minute infusion. The study was divided into three phases:
Phase 1: Non-dosing phase (Baseline). Phase 2: DEX preemptive analgesia phase (DEX infusion). Phase 3: DEX cessation phase (Post-infusion).
Outcomes:
Primary safety outcome: EEG spectral analysis at different phases. Secondary outcomes: NRS scores, postoperative nausea and vomiting (PONV), dizziness, agitation, and time to intestinal exhaust within 48 hours. Intraoperative hemodynamics were also monitored.